Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00443053
First received: March 2, 2007
Last updated: February 7, 2013
Last verified: February 2012
  Purpose

To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.


Condition Intervention Phase
Thrombosis, Venous
Superficial Thrombophlebitis
Drug: Fondaparinux 2.5mg or placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: See Detailed Description

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 [ Time Frame: Baseline to Day 47 ] [ Designated as safety issue: No ]
    VTE was defined as a composite of symptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), symptomatic extension of superficial vein thrombosis (SVT), or symptomatic recurrence of SVT. All VTEs were confirmed by objective tests and then adjudicated by an independent central adjudication committee (CAC), whose members were blinded to treatment assignment.


Secondary Outcome Measures:
  • Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77 [ Time Frame: Baseline to Day 77 ] [ Designated as safety issue: No ]
    VTE was defined as a composite of symptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), symptomatic extension of superficial vein thrombosis (SVT), or symptomatic recurrence of SVT. All VTEs were confirmed by objective tests and then adjudicated by an independent central adjudication committee (CAC), whose members were blinded to treatment assignment.

  • Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 [ Time Frame: Days 47 and 77 ] [ Designated as safety issue: No ]
    VTE was defined as a composite of symptomatic DVT; symptomatic PE; symptomatic extension of SVT, defined as downstream progression of the initial SVT by at least 2 cm and to within <=3 cm from the sapheno-femoral junction; or symptomatic recurrence of SVT, defined as a new episode in any other superficial venous location, meeting the following criteria: the new SVT was in a different superficial vein and not directly contiguous upstream with the index SVT, or it was in the same superficial vein but clearly distinct from the index SVT with an open venous segment of at least 10 cm in length.

  • Number of Participants Who Required Surgery to Treat Superficial Vein Thrombosis Recurrence at Days 47 and 77 [ Time Frame: Days 47 and 77 ] [ Designated as safety issue: No ]
    The number of participants requiring surgery was measured.

  • Number of Adjudicated Major Bleeding Events and Deaths at Days 47 and 77 [ Time Frame: Days 47 (or last dose plus 4 days) and 77 ] [ Designated as safety issue: No ]
    Major bleeding was defined as bleeding that was fatal and/or (1) in a critical area/organ (e.g., intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome); (2) associated with a fall in hemoglobin >=20 g/L (1.24 mmol/L); (3) led to a transfusion of >=2 units of packed red blood cells/whole blood. The revision of the Day 47 time point was to account for participants with treatment duration longer than 45 days. Adverse events were evaluated "On-Treatment," defined as from randomization up to the last injection +4 days.

  • Number of Adjudicated Non-Major Bleeding Events at Days 47 and 77 [ Time Frame: Days 47 (or last dose plus 4 days) and 77 ] [ Designated as safety issue: No ]
    Clinically relevant non-major bleeding was defined as clinically relevant bleeding that did not qualify as major but satisfied a priori criteria, and/or any bleeding that resulted in clinical consequences for a participant. The revision of the Day 47 time point was to account for participants with treatment duration longer than 45 days. Adverse events were evaluated "On-Treatment," defined as from randomization up to the last injection +4 days.

  • Number of Any Adjudicated Bleeding Events at Days 47 and 77 [ Time Frame: Days 47 (or last dose plus 4 days) and 77 ] [ Designated as safety issue: No ]
    The sum of adjudicated major bleeds, non-major clinically relevant bleeds, and minor bleeds was calculated. Minor bleeding was defined as other clinically overt bleeding events that did not meet the criteria for major or clinically relevant non-major bleeding. The revision of the Day 47 time point was to account for participants with treatment duration longer than 45 days. Adverse events were evaluated "On-Treatment," defined as from randomization up to the last injection +4 days.


Enrollment: 3002
Study Start Date: March 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fondaparinux 2.5mg Drug: Fondaparinux 2.5mg or placebo
Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
Placebo Comparator: Placebo Drug: Fondaparinux 2.5mg or placebo
Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day

Detailed Description:

Comparison of ARIXTRA™ in lower LImb Superficial Thrombophlebitis with placebo (CALISTO). An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Acute symptomatic superficial thrombophlebitis of the lower limbs at least 5 cm long diagnosed by compression ultrasound.

Exclusion criteria:

  • Superficial thrombophlebitis that is within 3 cm from the sapheno-femoral junction,
  • deep vein thrombosis on ultrasound exam, deep vein thrombosis or pulmonary embolism within last 6 months, treatment for cancer during last 6 months,
  • anticoagulant medication for more than 48 hours prior to inclusion,
  • need for oral non-steroidal anti-inflammatory drugs during the study, significant bleeding event during past month,
  • major surgery within last 3 months, low platelet count (below 100×109/L),
  • kidney disease (Calculated creatinine clearance < 30 mL/min), woman of child-bearing potential not using reliable contraceptive method
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00443053

  Hide Study Locations
Locations
Bulgaria
GSK Investigational Site
Sofia, Bulgaria, 1309
Czech Republic
GSK Investigational Site
Brno, Czech Republic, 656 91
GSK Investigational Site
Olomouc, Czech Republic, 775 20
GSK Investigational Site
Plzen, Czech Republic, 323 18
GSK Investigational Site
Praha 10, Czech Republic, 101 00
GSK Investigational Site
Praha 10, Czech Republic, 108 00
GSK Investigational Site
Praha 2, Czech Republic, 12808
GSK Investigational Site
Praha 4, Czech Republic, 140 00
GSK Investigational Site
Praha 5, Czech Republic, 150 05
GSK Investigational Site
Praha 6, Czech Republic, 169 02
GSK Investigational Site
Ricany, Czech Republic, 251 01
GSK Investigational Site
Tabor, Czech Republic, 390 03
Estonia
GSK Investigational Site
Saku, Estonia, 75501
GSK Investigational Site
Tallinn, Estonia, 10138
GSK Investigational Site
Tallinn, Estonia, 10617
GSK Investigational Site
Tartu, Estonia, 50410
France
GSK Investigational Site
Abbeville, France, 80100
GSK Investigational Site
Ales, France, 30100
GSK Investigational Site
Amiens, France, 80054
GSK Investigational Site
Annecy, France, 74000
GSK Investigational Site
Annonay, France, 07100
GSK Investigational Site
Arras, France, 62000
GSK Investigational Site
Bordeaux, France, 33082
GSK Investigational Site
Brest, France, 29200
GSK Investigational Site
Clermont Ferrand, France, 63000
GSK Investigational Site
Grenoble, France, 38000
GSK Investigational Site
Montpellier, France, 34295
GSK Investigational Site
Nice, France, 06000
GSK Investigational Site
Nîmes Cedex 9, France, 30029
GSK Investigational Site
Saint Aubin sur Scie, France, 76550
GSK Investigational Site
Saint-Priest en Jarez, France, 42270
GSK Investigational Site
Tarbes, France, 65000
GSK Investigational Site
Toulon, France, 83000
GSK Investigational Site
Toulouse, France, 31000
GSK Investigational Site
Valenciennes, France, 59300
GSK Investigational Site
Villeurbanne, France, 69100
Germany
GSK Investigational Site
Baesweiler, Baden-Wuerttemberg, Germany, 52499
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79108
GSK Investigational Site
Heidelberg, Baden-Wuerttemberg, Germany, 69120
GSK Investigational Site
Karlsbad, Baden-Wuerttemberg, Germany, 76307
GSK Investigational Site
Karlsruhe, Baden-Wuerttemberg, Germany, 76133
GSK Investigational Site
Lauffen, Baden-Wuerttemberg, Germany, 74348
GSK Investigational Site
Augsburg, Bayern, Germany, 86150
GSK Investigational Site
Grossheirath, Bayern, Germany, 96269
GSK Investigational Site
Hemau, Bayern, Germany, 93155
GSK Investigational Site
Muehldorf, Bayern, Germany, 84453
GSK Investigational Site
Muenchen, Bayern, Germany, 80331
GSK Investigational Site
Muenchen, Bayern, Germany, 80333
GSK Investigational Site
Muenchen, Bayern, Germany, 80336
GSK Investigational Site
Noerdlingen, Bayern, Germany, 86720
GSK Investigational Site
Nuernberg, Bayern, Germany, 90429
GSK Investigational Site
Wuerzburg, Bayern, Germany, 97070
GSK Investigational Site
Dahlwitz-Hoppegarten, Brandenburg, Germany, 15366
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14482
GSK Investigational Site
Darmstadt, Hessen, Germany, 64283
GSK Investigational Site
Eschwege, Hessen, Germany, 37269
GSK Investigational Site
Frankfurt, Hessen, Germany, 60322
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65183
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18059
GSK Investigational Site
Bad Bevensen, Niedersachsen, Germany, 29549
GSK Investigational Site
Leer, Niedersachsen, Germany, 26789
GSK Investigational Site
Osnabrueck, Niedersachsen, Germany, 49074
GSK Investigational Site
Essen-Kettwig, Nordrhein-Westfalen, Germany, 45219
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50760
GSK Investigational Site
Koeln-Junkersdorf, Nordrhein-Westfalen, Germany, 50858
GSK Investigational Site
Moenchengladbach, Nordrhein-Westfalen, Germany, 41065
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41460
GSK Investigational Site
Oberhausen, Nordrhein-Westfalen, Germany, 46145
GSK Investigational Site
Waldbroel, Nordrhein-Westfalen, Germany, 51545
GSK Investigational Site
Wuppertal, Nordrhein-Westfalen, Germany, 42275
GSK Investigational Site
Frankenthal, Rheinland-Pfalz, Germany, 67227
GSK Investigational Site
Ludwigshafen, Rheinland-Pfalz, Germany, 67059
GSK Investigational Site
Neustadt, Rheinland-Pfalz, Germany, 67434
GSK Investigational Site
Neunkirchen, Saarland, Germany, 66538
GSK Investigational Site
Chemnitz, Sachsen, Germany, 09130
GSK Investigational Site
Dresden, Sachsen, Germany, 01309
GSK Investigational Site
Kirchberg, Sachsen, Germany, 08107
GSK Investigational Site
Leipzig, Sachsen, Germany, 04109
GSK Investigational Site
Altenburg, Thueringen, Germany, 04600
GSK Investigational Site
Jena, Thueringen, Germany, 07743
GSK Investigational Site
Nordhausen, Thueringen, Germany, 99734
GSK Investigational Site
Berlin, Germany, 12627
GSK Investigational Site
Berlin, Germany, 10559
GSK Investigational Site
Berlin, Germany, 10789
GSK Investigational Site
Hamburg, Germany, 22143
GSK Investigational Site
Hamburg, Germany, 22177
GSK Investigational Site
Hamburg, Germany, 22761
GSK Investigational Site
Hamburg, Germany, 22081
Greece
GSK Investigational Site
Alexandroupolis, Greece, 68100
GSK Investigational Site
Athens, Greece, 145 61
GSK Investigational Site
Athens, Greece, 115 27
GSK Investigational Site
Heraklion, Greece, 712 01
GSK Investigational Site
Larisa, Greece, 41110
GSK Investigational Site
Melissia Athens, Greece, 15127
GSK Investigational Site
Thessaloniki, Greece, 56429
GSK Investigational Site
Thessaloniki, Greece, 54642
Hungary
GSK Investigational Site
Bekescsaba, Hungary, 5600
GSK Investigational Site
Budapest, Hungary, 1083
GSK Investigational Site
Budapest, Hungary, 1039
GSK Investigational Site
Budapest, Hungary, 1106
GSK Investigational Site
Budapest, Hungary, 1115
GSK Investigational Site
Budapest, Hungary, 1096
GSK Investigational Site
Budapest, Hungary, 1081
GSK Investigational Site
Budapest, Hungary, 1122
GSK Investigational Site
Debrecen, Hungary, 4032
GSK Investigational Site
Esztergom, Hungary, 2500
GSK Investigational Site
Gyula, Hungary, 5700
GSK Investigational Site
Kaposvár, Hungary, 7400
GSK Investigational Site
Miskolc, Hungary, 3501
GSK Investigational Site
Nyiregyháza, Hungary, 4400
GSK Investigational Site
Pécs, Hungary, 7623
GSK Investigational Site
Szikszó, Hungary, 8300
GSK Investigational Site
Székesfehérvár, Hungary, 8000
GSK Investigational Site
Zalaegerszeg, Hungary, 8900
Israel
GSK Investigational Site
Afula, Israel, 18101
GSK Investigational Site
Ashkelon, Israel, 78306
GSK Investigational Site
Haifa, Israel, 31096
GSK Investigational Site
Kfar Saba, Israel, 44281
GSK Investigational Site
Petach Tikva, Israel, 49100
GSK Investigational Site
Safed, Israel, 13110
GSK Investigational Site
Tel-Aviv, Israel, 64239
Italy
GSK Investigational Site
Chieti Scalo, Abruzzo, Italy, 66013
GSK Investigational Site
Napoli, Campania, Italy, 80131
GSK Investigational Site
Piacenza, Emilia-Romagna, Italy, 29100
GSK Investigational Site
Reggio Emilia, Emilia-Romagna, Italy, 42100
GSK Investigational Site
Rimini, Emilia-Romagna, Italy, 47900
GSK Investigational Site
Milano, Lombardia, Italy, 20142
GSK Investigational Site
Milano, Lombardia, Italy, 20132
GSK Investigational Site
Milano, Lombardia, Italy, 20122
GSK Investigational Site
Pavia, Lombardia, Italy, 27100
GSK Investigational Site
Palermo, Sicilia, Italy, 90126
GSK Investigational Site
Firenze, Toscana, Italy, 50134
GSK Investigational Site
Padova, Veneto, Italy, 35128
GSK Investigational Site
Venezia, Veneto, Italy, 30122
Latvia
GSK Investigational Site
Daugavpils, Latvia, LV5417
GSK Investigational Site
Riga, Latvia, LV 1012
GSK Investigational Site
Riga, Latvia, LV1038
GSK Investigational Site
Riga, Latvia, LV 1002
Netherlands
GSK Investigational Site
Alkmaar, Netherlands, 1815 KX
GSK Investigational Site
Amsterdam, Netherlands, 1066 EC
GSK Investigational Site
Amsterdam, Netherlands, 1105 AZ
GSK Investigational Site
Den Haag, Netherlands, 2566 MJ
GSK Investigational Site
Maastricht, Netherlands, 6229 HX
GSK Investigational Site
Weerselo, Netherlands, 7651 JH
Poland
GSK Investigational Site
Bialystok, Poland, 15-276
GSK Investigational Site
Bydgoszcz, Poland, 85-168
GSK Investigational Site
Gniewkowo, Poland, 88-140
GSK Investigational Site
Grudziadz, Poland, 86-300
GSK Investigational Site
Poznan, Poland, 61-848
GSK Investigational Site
Wroclaw, Poland, 50-349
Russian Federation
GSK Investigational Site
Arkhangelsk, Russian Federation, 163045
GSK Investigational Site
Barnaul, Russian Federation, 656038
GSK Investigational Site
Ekaterinburg, Russian Federation, 620028
GSK Investigational Site
Ekaterinburg, Russian Federation, 620102
GSK Investigational Site
Irkutsk, Russian Federation, 664003
GSK Investigational Site
Kemerovo, Russian Federation, 650002
GSK Investigational Site
Kursk, Russian Federation, 305035
GSK Investigational Site
Lipetsk, Russian Federation, 398055
GSK Investigational Site
Moscow, Russian Federation, 119049
GSK Investigational Site
Moscow, Russian Federation, 125299
GSK Investigational Site
Moscow, Russian Federation, 111538
GSK Investigational Site
Moscow, Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 115 280
GSK Investigational Site
Moscow, Russian Federation, 630117
GSK Investigational Site
Moscow, Russian Federation, 119 048
GSK Investigational Site
Perm, Russian Federation, 614107
GSK Investigational Site
Perm, Russian Federation, 614990
GSK Investigational Site
Rostov-na-Donu, Russian Federation, 344019
GSK Investigational Site
Ryazan, Russian Federation, 390026
GSK Investigational Site
Saint-Petersburg, Russian Federation, 198260
GSK Investigational Site
Saint-Petersburg, Russian Federation, 197046
GSK Investigational Site
Samara, Russian Federation, 443099
GSK Investigational Site
Saratov, Russian Federation, 4100017
GSK Investigational Site
St. Petersburgh, Russian Federation, 192242
GSK Investigational Site
Stavropol, Russian Federation, 310
GSK Investigational Site
Tomsk, Russian Federation, 630117
GSK Investigational Site
Tomsk, Russian Federation, 634063
GSK Investigational Site
Tumen, Russian Federation, 625023
GSK Investigational Site
Ufa, Russian Federation, 450000
GSK Investigational Site
Voronezh, Russian Federation, 394066
GSK Investigational Site
Yaroslavl, Russian Federation, 150023
GSK Investigational Site
Yaroslavl, Russian Federation, 150003
Slovakia
GSK Investigational Site
Bardejov, Slovakia, 085 01
GSK Investigational Site
Bratislava, Slovakia, 813 69
GSK Investigational Site
Bratislava, Slovakia, 833 05
GSK Investigational Site
Kosice, Slovakia, 040 01
GSK Investigational Site
Kosice, Slovakia, 040 86
GSK Investigational Site
Nitra, Slovakia, 949 01
GSK Investigational Site
Presov, Slovakia, 080 01
GSK Investigational Site
Zilina, Slovakia, 010 01
Spain
GSK Investigational Site
Avila, Spain, 05071
GSK Investigational Site
Boadilla del Monte (Madrid), Spain, 28660
GSK Investigational Site
Cartagena (Murcia), Spain, 30203
GSK Investigational Site
Getafe, Spain, 28905
GSK Investigational Site
Gijon, Spain, 33394
GSK Investigational Site
Hospitalet de Llobregat, Spain, 08907
GSK Investigational Site
Marid, Spain, 28040
GSK Investigational Site
Mataro, Spain, 08034
GSK Investigational Site
Palma de Mallorca, Spain, 07014
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
GSK Investigational Site
San Juan De Alicante, Spain, 3550
GSK Investigational Site
Segovia, Spain, 40002
GSK Investigational Site
Valencia, Spain, 46017
GSK Investigational Site
Valladolid, Spain, 47005
GSK Investigational Site
Zamora, Spain, 49021
Switzerland
GSK Investigational Site
Bern, Switzerland, 3010
GSK Investigational Site
Bruderholz, Switzerland, 4101
GSK Investigational Site
Fribourg, Switzerland, 1708
GSK Investigational Site
Geneve, Switzerland, 1211
GSK Investigational Site
Lausanne, Switzerland, 1005
GSK Investigational Site
Luzern, Switzerland, 6000
GSK Investigational Site
Zuerich, Switzerland, 8091
Ukraine
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49102
GSK Investigational Site
Dnipropetrovsk, Ukraine, 49005
GSK Investigational Site
Donetsk, Ukraine, 83045
GSK Investigational Site
Ivano-Frankivsk, Ukraine, 76000
GSK Investigational Site
Kharkiv, Ukraine, 61018
GSK Investigational Site
Kyiv, Ukraine, 04201
GSK Investigational Site
Kyiv, Ukraine, 01601
GSK Investigational Site
Kyiv, Ukraine, 03680
GSK Investigational Site
Lviv, Ukraine, 79010
GSK Investigational Site
Sevastopol, Ukraine, 99011
GSK Investigational Site
Uzhgorod, Ukraine, 88010
GSK Investigational Site
Vinnitsa, Ukraine, 21018
GSK Investigational Site
Zaporizhzhya, Ukraine, 69000
GSK Investigational Site
Zaporizhzhya, Ukraine, 69065
GSK Investigational Site
Zaporizhzhya, Ukraine, 69600
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00443053     History of Changes
Other Study ID Numbers: ART108053
Study First Received: March 2, 2007
Results First Received: July 2, 2010
Last Updated: February 7, 2013
Health Authority: Netherlands: Medicines Evaluation Board (MEB)

Keywords provided by GlaxoSmithKline:
superficial vein thrombosis
superficial thrombophlebitis
fondaparinux
deep vein thrombosis
venous thromboembolism treatment
thrombosis

Additional relevant MeSH terms:
Thrombophlebitis
Thrombosis
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Phlebitis
Peripheral Vascular Diseases
Vasculitis
Fondaparinux
PENTA
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on July 22, 2014